Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for IGM Biosciences, Inc. (IGMS : NSDQ)
 
 • Company Description   
IGM Biosciences Inc. is a biotechnology company. It engages in the research and development of engineered Immunoglobulin M antibodies for the treatment of cancer patients. The company's lead product candidate is IGM-2323, a bispecific T cell engaging IgM, which are in clinical stage. IGM Biosciences Inc. is based in Mountain View, California.

Number of Employees: 149

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.14 Daily Weekly Monthly
20 Day Moving Average: 153,975 shares
Shares Outstanding: 59.78 (millions)
Market Capitalization: $68.14 (millions)
Beta: 0.61
52 Week High: $22.50
52 Week Low: $0.92
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 7.55% 4.22%
12 Week -17.39% -11.22%
Year To Date -81.34% -80.51%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
325 EAST MIDDLEFIELD ROAD
-
MOUNTAIN VIEW,CA 94043
USA
ph: 650-965-7873
fax: -
None http://igmbio.com
 
 • General Corporate Information   
Officers
Mary Beth Harler - Chief Executive Officer and Director
Misbah Tahir - Chief Financial Officer
Steven Weber - Senior Vice President; Corporate Controller
Felix Baker - Director
M. Kathleen Behrens - Director

Peer Information
IGM Biosciences, Inc. (CORR.)
IGM Biosciences, Inc. (RSPI)
IGM Biosciences, Inc. (CGXP)
IGM Biosciences, Inc. (BGEN)
IGM Biosciences, Inc. (GTBP)
IGM Biosciences, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 449585108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 12/01/24
Next Expected EPS Date: 05/14/25
Share - Related Items
Shares Outstanding: 59.78
Most Recent Split Date: (:1)
Beta: 0.61
Market Capitalization: $68.14 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.31 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.05 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 38.98% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 05/14/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.39
Price/Cash Flow: -
Price / Sales: 25.44
EPS Growth
vs. Year Ago Period: 39.60%
vs. Previous Quarter: 39.60%
Sales Growth
vs. Year Ago Period: -36.71%
vs. Previous Quarter: -20.16%
ROE
03/31/25 - -
12/31/24 - -190.68
09/30/24 - -155.42
ROA
03/31/25 - -
12/31/24 - -61.05
09/30/24 - -61.04
Current Ratio
03/31/25 - -
12/31/24 - 5.14
09/30/24 - 5.22
Quick Ratio
03/31/25 - -
12/31/24 - 5.14
09/30/24 - 5.22
Operating Margin
03/31/25 - -
12/31/24 - -7,308.51
09/30/24 - -7,534.03
Net Margin
03/31/25 - -
12/31/24 - -7,308.51
09/30/24 - -7,534.03
Pre-Tax Margin
03/31/25 - -
12/31/24 - -7,308.51
09/30/24 - -7,525.74
Book Value
03/31/25 - -
12/31/24 - 0.82
09/30/24 - 1.33
Inventory Turnover
03/31/25 - -
12/31/24 - -
09/30/24 - -
Debt-to-Equity
03/31/25 - -
12/31/24 - 0.00
09/30/24 - 0.00
Debt-to-Capital
03/31/25 - -
12/31/24 - 0.00
09/30/24 - 0.00
 

Powered by Zacks Investment Research ©